Status note Lead program: in vivo gene editing for hemoglobinopathies; company focusing resources on advancing to human proof-of-concept.
renizgamglogene autogedtemcel (reni-cel)
Stage not disclosed · TerminatedModality: Ex vivo gene-edited cell medicine (AsCas12a)
Target HBG1/HBG2 promoter (gamma-globin)
Indications
Sickle cell disease / transfusion-dependent beta thalassemia(Stage not disclosed)
Status note Dec 2024: board approved discontinuation of clinical development; company ceased activities toward BLA filing and potential commercialization to optimize cost structure and accelerate in vivo gene editing. Approximately 180 positions (65%) eliminated in associated restructuring.
CD19 HD Allo CAR T (BMS program)
Phase 1 · ActiveModality: Allogeneic CAR T
Target CD19
Partnerships BMS (via Juno Therapeutics): collaboration and license; Editas provides Cas9/AsCas12a platform; BMS funds and owns development. One of 14 programs under the collaboration; Immatics non-exclusive gamma-delta T cell collaboration programs not named.
Indications
Autoimmune disease(Phase 1)
Status note BMS' program using Editas platform technology; one of 14 programs under the BMS collaboration. Other named programs: Immatics non-exclusive gamma-delta T cell collaboration (programs not named).
Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.